ATE258227T1 - Methode zur in vitro reproduktion der rna- abhängigen rna polymerase- und terminalen nukleotidyltransferase-aktivität des hepatitis c virus (hcv) - Google Patents

Methode zur in vitro reproduktion der rna- abhängigen rna polymerase- und terminalen nukleotidyltransferase-aktivität des hepatitis c virus (hcv)

Info

Publication number
ATE258227T1
ATE258227T1 AT96916289T AT96916289T ATE258227T1 AT E258227 T1 ATE258227 T1 AT E258227T1 AT 96916289 T AT96916289 T AT 96916289T AT 96916289 T AT96916289 T AT 96916289T AT E258227 T1 ATE258227 T1 AT E258227T1
Authority
AT
Austria
Prior art keywords
hcv
hepatitis
virus
rna
transferase activity
Prior art date
Application number
AT96916289T
Other languages
English (en)
Inventor
Francesco Raffaele De
Licia Tomei
Sven-Erik Behrens
Original Assignee
Angeletti P Ist Richerche Bio
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=11403393&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE258227(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Angeletti P Ist Richerche Bio filed Critical Angeletti P Ist Richerche Bio
Application granted granted Critical
Publication of ATE258227T1 publication Critical patent/ATE258227T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/026—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a baculovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96916289T 1995-05-25 1996-05-24 Methode zur in vitro reproduktion der rna- abhängigen rna polymerase- und terminalen nukleotidyltransferase-aktivität des hepatitis c virus (hcv) ATE258227T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95RM000343A IT1278077B1 (it) 1995-05-25 1995-05-25 Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
PCT/IT1996/000106 WO1996037619A1 (en) 1995-05-25 1996-05-24 Method for reproducing in vitro the rna-dependent rna polymerase and terminal nucleotidyl transferase activities encoded by hepatitis c virus (hcv)

Publications (1)

Publication Number Publication Date
ATE258227T1 true ATE258227T1 (de) 2004-02-15

Family

ID=11403393

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96916289T ATE258227T1 (de) 1995-05-25 1996-05-24 Methode zur in vitro reproduktion der rna- abhängigen rna polymerase- und terminalen nukleotidyltransferase-aktivität des hepatitis c virus (hcv)

Country Status (13)

Country Link
US (2) US6383768B1 (de)
EP (1) EP0842276B1 (de)
JP (1) JP3187432B2 (de)
AT (1) ATE258227T1 (de)
AU (1) AU708431B2 (de)
BR (1) BR9609178A (de)
CA (1) CA2220873C (de)
DE (1) DE69631375T2 (de)
DK (1) DK0842276T3 (de)
ES (1) ES2211956T3 (de)
IT (1) IT1278077B1 (de)
PT (1) PT842276E (de)
WO (1) WO1996037619A1 (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
ATE318896T1 (de) * 1995-09-27 2006-03-15 Univ Emory Rekombinante rna-replikase von hepatitis-c-virus
US6461845B1 (en) * 1995-09-27 2002-10-08 Emory University Recombinant hepatitis C virus RNA replicase
EP1037974B1 (de) * 1997-12-11 2007-10-03 SmithKline Beecham Corporation Verkürztes hepatitis-c-virus protein nsb5 und methoden, um antivirale substanzen zu identifizieren
EP1068362A4 (de) * 1998-04-02 2005-07-20 Viropharma Inc Hepatitis c virus ns5b zusammensetzungen und verfahren zu deren verwendung
AU4393399A (en) * 1998-06-24 2000-01-10 Chugai Seiyaku Kabushiki Kaisha Hcv-derived rna polymerase gene
WO2000033635A2 (en) * 1998-12-10 2000-06-15 Eli Lilly And Company Primer-independent rna synthesis catalyzed by hcv polymerase
US6297005B1 (en) 1999-05-04 2001-10-02 Schering Corporation De novo priming activity of hepatitis C virus replicase
WO2001038538A1 (en) * 1999-11-23 2001-05-31 Viropharma Incorporated Polymerase compositions and methods of use thereof
EP1270737A4 (de) * 2000-04-07 2004-06-16 Shionogi & Co Testverfahren mit vorinkubationsschritt
KR20020010241A (ko) * 2000-07-28 2002-02-04 허영섭 Ｃ형 간염 바이러스 ｒｎａ-의존성 ｒｎａ 중합효소의대량 발현 기구 및 이로부터 발현된 융합단백질을 이용한효소활성 분석방법
WO2002059321A2 (en) 2001-01-23 2002-08-01 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Hepatitis c virus replicons and replicon enhanced cells
CN1582337B (zh) 2001-10-11 2011-12-14 默沙东公司 丙型肝炎病毒疫苗
CN101988071B (zh) 2001-10-11 2016-07-06 默沙东公司 丙型肝炎病毒疫苗
ATE426682T1 (de) 2002-04-16 2009-04-15 Merck & Co Inc Hepatitis-c-virus-testsysteme
TW200400818A (en) 2002-05-21 2004-01-16 Wyeth Corp Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
TW200400963A (en) 2002-05-21 2004-01-16 Wyeth Corp R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
US20040142322A1 (en) * 2002-10-07 2004-07-22 Schering Corporation Continuous non-radioactive polymerase assay
US7408078B2 (en) * 2002-10-08 2008-08-05 Wyeth Anthranilic acid derivatives useful in treating infection with hepatitis C virus
CA2514918C (en) 2003-02-13 2012-07-03 Merck & Co., Inc. Method to confer cell culture replication activity to different hepatitis c virus isolates
WO2005047463A2 (en) 2003-11-05 2005-05-26 Merck & Co., Inc. Hcv replicons containing ns5b from genotype 2b
WO2005070957A1 (en) 2004-01-09 2005-08-04 Merck & Co., Inc. Hcv rna-dependent rna polymerase
EP1735470B1 (de) * 2004-03-24 2010-04-21 Achillion Pharmaceuticals, Inc. Quantitativer test zum nachweis neu synthetisierter rna in einem zellfreien system sowie identifizierung von inhibitoren der rna-synthese
JP2008517987A (ja) 2004-10-26 2008-05-29 イステイチユート・デイ・リチエルケ・デイ・ビオロジア・モレコラーレ・ピ・アンジエレツテイ・エツセ・ピー・アー 抗ウイルス薬としての四環式インドール誘導体
EP1874952A2 (de) * 2005-04-11 2008-01-09 Achillion Pharmaceuticals, Inc. Pharmazeutische zusammensetzungen und verfahren zur hemmung der hcv-replikation
GB0608928D0 (en) 2006-05-08 2006-06-14 Angeletti P Ist Richerche Bio Therapeutic agents
EP2029741A4 (de) 2006-06-08 2011-03-16 Merck Sharp & Dohme Schnellverfahren zur bestimmung der hemmersensitivität von aus klinischen proben geklonten ns3/4a-proteasesequenzen
GB0625345D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
GB0625349D0 (en) 2006-12-20 2007-01-31 Angeletti P Ist Richerche Bio Therapeutic compounds
CA2674831A1 (en) 2006-12-22 2008-11-13 Schering Corporation 5,6-ring annulated indole derivatives and methods of use thereof
JP5079818B2 (ja) 2006-12-22 2012-11-21 メルク・シャープ・アンド・ドーム・コーポレーション Ｈｃｖおよび関連するウイルス疾患の治療または予防のための４，５−環インドール誘導体
CA2673254C (en) 2006-12-22 2013-09-10 Schering Corporation 4,5-ring annulated indole derivatives for treating or preventing of hcv and related viral infections
EP2481807A3 (de) 2007-03-09 2013-04-03 Merck Sharp & Dohme Corp. In-vivo-HCV-Resistenz gegen antivirale Hemmer
WO2009010785A1 (en) 2007-07-17 2009-01-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti Spa Macrocyclic indole derivatives for the treatment of hepatitis c infections
PE20090994A1 (es) 2007-08-29 2009-08-03 Schering Corp Derivados de azaindol 2,3-sustituidos como agentes antivirales
AU2008295484B2 (en) 2007-08-29 2013-09-26 Merck Sharp & Dohme Llc Substituted indole derivatives and methods of use thereof
CN101842353A (zh) 2007-08-29 2010-09-22 先灵公司 用于治疗病毒感染的2,3-取代的吲哚衍生物
EP2222660B1 (de) 2007-11-16 2014-03-26 Merck Sharp & Dohme Corp. 3-heterocyclylsubstituierte indolderivate und verfahren zu deren anwendung
JP5416708B2 (ja) 2007-11-16 2014-02-12 メルク・シャープ・アンド・ドーム・コーポレーション ３−アミノスルホニル置換インドール誘導体およびそれらの使用方法
WO2009152200A1 (en) 2008-06-13 2009-12-17 Schering Corporation Tricyclic indole derivatives and methods of use thereof
EP2166016A1 (de) 2008-09-18 2010-03-24 Centocor Ortho Biotech Products L.P. Phosphoramidat-Derivate von Nukleosiden
WO2010082050A1 (en) 2009-01-16 2010-07-22 Istituto Di Ricerche Di Biologia Molecolare P. Angeletti S.P.A. Macrocyclic and 7-aminoalkyl-substituted benzoxazocines for treatment of hepatitis c infections
GB0906026D0 (en) 2009-04-07 2009-05-20 Angeletti P Ist Richerche Bio Therapeutic compounds
CN102686599B (zh) 2009-09-29 2016-10-05 杨森产品有限公司 核苷的氨基磷酸酯衍生物
WO2014139587A1 (en) 2013-03-15 2014-09-18 Okairòs Ag Improved poxviral vaccines
WO2017025782A1 (en) 2014-09-17 2017-02-16 Glaxosmithkline Biologicals Sa Improved poxviral vaccines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0464287A1 (de) * 1990-06-25 1992-01-08 The Research Foundation for Microbial Diseases of Osaka University Non-A, Non-B Hepatitis Virus genomisches DNS und Antigenpolypeptide
CA2045326A1 (en) * 1990-06-25 1991-12-26 Hiroto Okayama Non-a, non-b, hepatitis virus particles
US5360714A (en) * 1992-08-28 1994-11-01 Fox Chase Cancer Center Hepadnavirus polymerase gene product having RNA-dependent DNA priming and reverse transcriptase activities and methods of measuring the activities thereof
IT1272179B (it) * 1994-02-23 1997-06-16 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro l'attivita' proteolitica della proteasi ns3 del virus hcv.
IT1278077B1 (it) * 1995-05-25 1997-11-17 Angeletti P Ist Richerche Bio Metodologia per riprodurre in vitro le attivita' di rna polimerasi rna-dipendente e di nucleotidiltransferasi terminale codificate dal
ATE318896T1 (de) 1995-09-27 2006-03-15 Univ Emory Rekombinante rna-replikase von hepatitis-c-virus

Also Published As

Publication number Publication date
BR9609178A (pt) 1999-05-04
AU5909896A (en) 1996-12-11
US7399605B2 (en) 2008-07-15
JPH10507370A (ja) 1998-07-21
DE69631375D1 (de) 2004-02-26
ITRM950343A0 (it) 1995-05-25
DK0842276T3 (da) 2004-05-03
WO1996037619A1 (en) 1996-11-28
IT1278077B1 (it) 1997-11-17
AU708431B2 (en) 1999-08-05
PT842276E (pt) 2004-05-31
EP0842276A1 (de) 1998-05-20
EP0842276B1 (de) 2004-01-21
US6383768B1 (en) 2002-05-07
CA2220873C (en) 2000-10-24
JP3187432B2 (ja) 2001-07-11
DE69631375T2 (de) 2004-11-04
CA2220873A1 (en) 1996-11-28
US20020164722A1 (en) 2002-11-07
ES2211956T3 (es) 2004-07-16
ITRM950343A1 (it) 1996-11-25

Similar Documents

Publication Publication Date Title
ATE258227T1 (de) Methode zur in vitro reproduktion der rna- abhängigen rna polymerase- und terminalen nukleotidyltransferase-aktivität des hepatitis c virus (hcv)
Friebe et al. Sequences in the 5′ nontranslated region of hepatitis C virus required for RNA replication
Krieger et al. Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations
DK0585398T3 (da) HCV genomiske sekvenser til diagnostiske og terapeutiske midler
HUP0203305A2 (hu) Fertőző klónok
DE60142562D1 (de) Immunostimulierende polynukleotide sequenzen zur verwendung bei der unterdrückung von hepatitis virus infektion
DK0484787T3 (da) HCV-specifikke peptider, fremgangsmåde til opnåelse deraf og anvendelse deraf
DK1187852T3 (da) Ekspression og eksport af interferon-alpha-proteiner som Fc-fusionsproteiner
ATE281647T1 (de) Verfahren zur typisierung von hepatitis c viren und dafür zu verwendende reagenzien
ATE327246T1 (de) Hepatitis c tripeptid inhibitoren
TR199901602T2 (xx) Serin proteazlar�n ve �zel olarak hepatit C vir�s� NS3 proteaz�n�n inhibit�rleri.
DE69333914D1 (de) Verfahren und zusammensetzungen zur kontrolle der übersetzung der hcv-proteine
DE69334328D1 (de) Antigene Peptide zur Gruppierung des Hepatitis-C-Virus, Kit damit und Verfahren zur Gruppierung unter Verwendung dieses Kits
ATE337404T1 (de) Zur verleihung viraler resistenz an pflanzen geeignetes polyribozym und dieses polyribozym produzierende resistente pflanzen
DK0551275T3 (da) Non-A non-B sekvenser
DK1417233T3 (da) Humant rekombinant antistof mod det hepatitis C (HCV) ikke-strukturelle NS3-protein, nukleinsyre og anvendelser deraf
IL137458A0 (en) Genetic immunization with nonstructural proteins of hepatitis c virus
WO2002072776A3 (en) Cell culture system for synthesis of infectious hepatitis c virus
GB9912432D0 (en) Novel gbv sequence
NO20000537D0 (no) Oligonukleotidprimere for effektiv reverstranskripsjon av Hepatitis C-virus (HCV) RNA og metoder for anvendelse derav
AU2180997A (en) Isolation and/or amplification of hepatitis c virus (hcv) nucleic acids from samples suspected to contain hcv
AU2002337378A1 (en) Screening for antiviral affecting signal peptidase
EP1424390A4 (de) Intakter hepatitis-c-virus und verfahren zu seiner kultivierung in einer in-vitro-zellkultur
KR970021307A (ko) HCV-신드비스(Sindbis) 재조합 바이러스 클론 및 그를 이용한 C형 간염 치료제의 탐색방법

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0842276

Country of ref document: EP